ArticleBlood2019
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
17.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 230 citations in OpenAlex.
- Trial
- Trial
- Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.Nature communications · 2024Trial
- Trial
- Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.Haematologica · 2020Trial
- Trial
- Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.The Lancet. Oncology · 2019Trial
- To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.European journal of haematology · 2026Review
- Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.British journal of haematology · 2026Article
- Cytogenetic Characteristics of Chronic Lymphocytic Leukemia Patients: A Single-Center Study From Morocco.Cureus · 2026Article
- Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.British journal of haematology · 2026Article
- ComplexInternational journal of molecular sciences · 2026Review
- Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Leveraging a spectrum of cytogenomics methods for profiling complex karyotypes in chronic lymphocytic leukemia.Human genomics · 2026Article
- Article
- Exploring the synergy between telomere length and genomic complexity in CLL.British journal of haematology · 2026Article
- Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.Blood advances · 2026Article
- Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
43 authors at 20 institutions in 10 countries.
Panagiotis BaliakasDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Sabine JerominMLL Munich Leukemia Laboratory, Munich, Germany.
Michalis IskasHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Anna PuiggrosLaboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain.
Karla PlevovaCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Florence Nguyen-KhacHematology Department and Sorbonne University, Hopital Pitie-Salpetriere, INSERM U1138, Paris, France.
Zadie DavisDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
Gian Matteo RigolinHematology Section, St. Anna University Hospital, Ferrara, Italy.
Andrea VisentinHematology Division, Department of Medicine, University of Padua, Padua, Italy.
Aliki XochelliInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Julio DelgadoDepartment of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
Fanny Baran-MarszakLaboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France.
Evangelia StalikaInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Pau AbrisquetaServei d'Hematología, Hospital Vall d'Hebron, Barcelona, Spain.
Kristina DurechovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
George PapaioannouHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Virginie EclacheLaboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France.
Maria DimouHematology Section, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.
Theodoros IliakisHematology Section, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.
Rosa ColladoServicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain.
Michael DoubekCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
M Jose CalasanzServicio de Genética Citogenética, Departamento de Genética, Universidad de Navarra, Pamplona, Spain.
Neus Ruiz-XivilleServei Laboratori Hematologia, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma de Barcelona, Badalona, Spain.
Carolina MorenoServei d'Hematologia, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
Marie JarosovaCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Alexander C LeeksmaDepartment of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
Panayiotis PanayiotidisHematology Section, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.
Helena PodgornikDepartment of Hematology, University Medical Centre Ljubljana, Ljubljana, Slovenia; and.ORCID 0000-0003-3752-2067
Florence CymbalistaLaboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France.
Achilles AnagnostopoulosHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Livio TrentinHematology Division, Department of Medicine, University of Padua, Padua, Italy.
Niki StavroyianniHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Fred DaviHematology Department and Sorbonne University, Hopital Pitie-Salpetriere, INSERM U1138, Paris, France.
Paolo GhiaStrategic Research Program in CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy.
Arnon P KaterDepartment of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3190-1891
Antonio CuneoHematology Section, St. Anna University Hospital, Ferrara, Italy.
Sarka PospisilovaCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Blanca EspinetLaboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain.
Anastasia AthanasiadouHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
David OscierDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Kostas StamatopoulosDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
ERIC, the European Research Initiative on CLL
G. Papanikolaou General Hospital · GRCentral European Institute of Technology · CZAssistance Publique – Hôpitaux de Paris · FRNational and Kapodistrian University of Athens · GRAmsterdam UMC Location University of Amsterdam · NLCentre for Research and Technology Hellas · GRHospital Del Mar · ESInserm · FRMunich Leukemia Laboratory (Germany) · DERoyal Bournemouth Hospital · GBUniversity of Ferrara · ITUniversity of Padua · ITUppsala University · SEHospital de Sant Pau · ESHospital General Universitario De Valencia · ESLjubljana University Medical Centre · SIMasaryk University · CZUniversidad de Navarra · ESUniversitat Autònoma de Barcelona · ESUniversitat de Barcelona · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with ≥5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage,
Indexed as
Chromosome AberrationsMutationAgedBiomarkers, TumorCytogeneticsFemaleFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPrognosisRetrospective StudiesSomatic Hypermutation, ImmunoglobulinSurvival RateTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.